Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01867125
Registration number
NCT01867125
Ethics application status
Date submitted
29/05/2013
Date registered
3/06/2013
Date last updated
19/05/2017
Titles & IDs
Public title
A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
Query!
Scientific title
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lebrikizumab in Patients With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication
Query!
Secondary ID [1]
0
0
2013-000175-33
Query!
Secondary ID [2]
0
0
GB28688
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Asthma
0
0
Query!
Condition category
Condition code
Respiratory
0
0
0
0
Query!
Asthma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Lebrikizumab
Treatment: Drugs - Placebo
Experimental: Lebrikizumab (125 mg) - Participants will receive SC injection of lebrikizumab (125 milligrams \[mg\]) every 4 weeks for 104 weeks.
Experimental: Lebrikizumab (37.5 mg) - Participants will receive SC injection of lebrikizumab (37.5 mg) every 4 weeks for 104 weeks.
Placebo comparator: Placebo - Participants will receive SC injection of lebrikizumab matching placebo every 4 weeks for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at 125 or 37.5 mg for 52 weeks during active treatment extension period.
Treatment: Drugs: Lebrikizumab
Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
Treatment: Drugs: Placebo
Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Rate of Asthma Exacerbations During the 52-Week Placebo-Controlled Period
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline up to 52 weeks
Query!
Secondary outcome [1]
0
0
Absolute Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Baseline, Week 52
Query!
Secondary outcome [2]
0
0
Time to First Asthma Exacerbation
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
Baseline up to 52 weeks
Query!
Secondary outcome [3]
0
0
Change From Baseline in Standardized Asthma Quality of Life Questionnaire (AQLQ) Score
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
Baseline, Week 52
Query!
Secondary outcome [4]
0
0
Change from Baseline In Asthma Rescue Medication (Number of Puffs or Nebulized Treatments)
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
Baseline, Week 52
Query!
Secondary outcome [5]
0
0
Rate of Urgent Asthma-Related Urgent Health Care Utilization
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
Baseline up to Week 52
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Anti-Therapeutic Antibodies to Lebrikizumab
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
Baseline up to Week 124 (assessed at Baseline, Weeks 4, 12, 24, 36, 52, 64, 76, 92, 104, 112, and 124)
Query!
Secondary outcome [7]
0
0
Change From Baseline in Asthma Control Questionnaire-5 (ACQ-5) Score
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Baseline, Week 52
Query!
Secondary outcome [8]
0
0
Percentage of Participants With Adverse Events
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Baseline, Week 124
Query!
Secondary outcome [9]
0
0
Minimum Serum Concentration (Cmin) of Lebrikizumab
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Predose (0 hour) on Weeks 4, 12, 24, 36, and 52
Query!
Eligibility
Key inclusion criteria
* Asthma diagnosis for greater than equal to (>/=) 12 months prior to Visit 1
* Bronchodilator response at Visit 1, 2, or 3
* Pre-bronchodilator FEV1 of 40 percent (%) - 80% predicted at both Visits 2 and 3
* On ICS therapy at a total daily dose of 500-2000 micrograms (mcg) of fluticasone propionate dry powder inhaler (DPI) or equivalent for >/=6 months prior to Visit 1
* On an eligible second controller medication (long-acting beta-agonist [LABA], leukotriene receptor antagonist [LTRA], long-acting muscarinic antagonist [LAMA], or theophylline) for 6 months prior to Visit 1
* Uncontrolled asthma at Visit 1 and/or Visit 2, and at Visit 3
* Chest X-ray or computed tomography (CT) scan within 3 months prior to Visit 1 or chest X-ray during the screening period (prior to Visit 3) confirming the absence of other clinically significant lung disease
* Demonstrated adherence with controller medication during the screening period
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of the lebrikizumab injection
* Maintenance oral corticosteroid therapy within 3 months of Visit 1
* Treatment with systemic (oral, intravenous [IV], or intramuscular [IM]) corticosteroids within 4 weeks prior to Visit 1 or during the screening period
* Treatment with intra-articular corticosteroids within 4 weeks prior to Visit 1 or during the screening period or anticipated need for intra-articular corticosteroids during the course of the study
* Infection requiring hospital admission for >/=24 hours or requiring treatment with IV or IM antibiotics within 4 weeks prior to Visit 1 or during screening; Upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening; Active infection that required treatment with oral antibiotics within 2 weeks prior to Visit 1 or during screening; Active parasitic infection or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening
* Active tuberculosis requiring treatment within 12 months prior to Visit 1
* Known immunodeficiency, including, but not limited to, human immunodeficiency virus (HIV) infection
* Evidence of acute or chronic hepatitis or known liver cirrhosis
* History of interstitial lung disease, chronic obstructive pulmonary disease (COPD), or other clinically significant lung disease other than asthma
* Known current malignancy or current evaluation for potential malignancy
* Current smoker or former smoker with a history of greater than (>) 10 pack-years
* History of alcohol or drug abuse
* Past and/or current use of any anti-interleukin (IL)-13 or anti-IL-4/IL-13 therapy, including lebrikizumab
* Use of other monoclonal antibody therapy, including omalizumab, within 6 months or 5 drug half-lives prior to Visit 1 (whichever is longer) or during screening
* Initiation of or change in allergen immunotherapy within 3 months prior to Visit 1 or during screening
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/07/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
2/01/2017
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1081
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC,WA
Query!
Recruitment hospital [1]
0
0
Liverpool Hospital - Liverpool BC
Query!
Recruitment hospital [2]
0
0
St. Vincent's Hospital Melbourne - Fitzroy
Query!
Recruitment hospital [3]
0
0
Box Hill Hospital; Eastern Clinical Research Unit - Box Hill
Query!
Recruitment hospital [4]
0
0
Western Hospital - Footscray
Query!
Recruitment hospital [5]
0
0
The Lung Institute of Western Australia; Sir Charles Gairdner Hospital - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
1871 - Liverpool BC
Query!
Recruitment postcode(s) [2]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [3]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [4]
0
0
3011 - Footscray
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Connecticut
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Florida
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Georgia
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Massachusetts
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Montana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nebraska
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nevada
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Jersey
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Ohio
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Oklahoma
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Oregon
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Pennsylvania
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Rhode Island
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
South Carolina
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Texas
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Virginia
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
Washington
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Wisconsin
Query!
Country [29]
0
0
Argentina
Query!
State/province [29]
0
0
Buenos Aires
Query!
Country [30]
0
0
Argentina
Query!
State/province [30]
0
0
Mar Del Plata
Query!
Country [31]
0
0
Argentina
Query!
State/province [31]
0
0
Quilmes
Query!
Country [32]
0
0
Argentina
Query!
State/province [32]
0
0
San Miguel de Tucuman
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Bruxelles
Query!
Country [34]
0
0
Belgium
Query!
State/province [34]
0
0
Gent
Query!
Country [35]
0
0
Canada
Query!
State/province [35]
0
0
Alberta
Query!
Country [36]
0
0
Canada
Query!
State/province [36]
0
0
Ontario
Query!
Country [37]
0
0
Canada
Query!
State/province [37]
0
0
Quebec
Query!
Country [38]
0
0
Chile
Query!
State/province [38]
0
0
Santiago
Query!
Country [39]
0
0
Chile
Query!
State/province [39]
0
0
Valparaiso
Query!
Country [40]
0
0
Colombia
Query!
State/province [40]
0
0
Bogota DC
Query!
Country [41]
0
0
Czechia
Query!
State/province [41]
0
0
Jablonec Nad Nisou
Query!
Country [42]
0
0
Czechia
Query!
State/province [42]
0
0
Jindrichuv Hradec
Query!
Country [43]
0
0
Czechia
Query!
State/province [43]
0
0
Ostrava - Poruba
Query!
Country [44]
0
0
Czechia
Query!
State/province [44]
0
0
Teplice
Query!
Country [45]
0
0
France
Query!
State/province [45]
0
0
Lille
Query!
Country [46]
0
0
France
Query!
State/province [46]
0
0
Marseille
Query!
Country [47]
0
0
France
Query!
State/province [47]
0
0
Montpellier
Query!
Country [48]
0
0
France
Query!
State/province [48]
0
0
Nantes
Query!
Country [49]
0
0
France
Query!
State/province [49]
0
0
Strabourg
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Berlin
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Wiesloch
Query!
Country [52]
0
0
Hungary
Query!
State/province [52]
0
0
Debrecen
Query!
Country [53]
0
0
Hungary
Query!
State/province [53]
0
0
Gyor
Query!
Country [54]
0
0
Hungary
Query!
State/province [54]
0
0
Szeged
Query!
Country [55]
0
0
Israel
Query!
State/province [55]
0
0
Ashkelon
Query!
Country [56]
0
0
Israel
Query!
State/province [56]
0
0
Haifa
Query!
Country [57]
0
0
Israel
Query!
State/province [57]
0
0
Jerusalem
Query!
Country [58]
0
0
Israel
Query!
State/province [58]
0
0
Kfar Saba
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Rehovot
Query!
Country [60]
0
0
Italy
Query!
State/province [60]
0
0
Calabria
Query!
Country [61]
0
0
Italy
Query!
State/province [61]
0
0
Emilia-Romagna
Query!
Country [62]
0
0
Italy
Query!
State/province [62]
0
0
Marche
Query!
Country [63]
0
0
Italy
Query!
State/province [63]
0
0
Puglia
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Toscana
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Veneto
Query!
Country [66]
0
0
Japan
Query!
State/province [66]
0
0
Aichi
Query!
Country [67]
0
0
Japan
Query!
State/province [67]
0
0
Amagasaki-shi
Query!
Country [68]
0
0
Japan
Query!
State/province [68]
0
0
Fukuoka-shi
Query!
Country [69]
0
0
Japan
Query!
State/province [69]
0
0
Higashiibaraki-gun
Query!
Country [70]
0
0
Japan
Query!
State/province [70]
0
0
Hiroshima
Query!
Country [71]
0
0
Japan
Query!
State/province [71]
0
0
Hokkaido
Query!
Country [72]
0
0
Japan
Query!
State/province [72]
0
0
Iwate
Query!
Country [73]
0
0
Japan
Query!
State/province [73]
0
0
Kanagawa
Query!
Country [74]
0
0
Japan
Query!
State/province [74]
0
0
Kiyose-shi
Query!
Country [75]
0
0
Japan
Query!
State/province [75]
0
0
Kochi
Query!
Country [76]
0
0
Japan
Query!
State/province [76]
0
0
Kodaira-shi
Query!
Country [77]
0
0
Japan
Query!
State/province [77]
0
0
Kokubunji-shi
Query!
Country [78]
0
0
Japan
Query!
State/province [78]
0
0
Koshigaya-shi
Query!
Country [79]
0
0
Japan
Query!
State/province [79]
0
0
Mizunami-shi
Query!
Country [80]
0
0
Japan
Query!
State/province [80]
0
0
Nagaoka-shi
Query!
Country [81]
0
0
Japan
Query!
State/province [81]
0
0
Niigata-shi
Query!
Country [82]
0
0
Japan
Query!
State/province [82]
0
0
Osaka
Query!
Country [83]
0
0
Japan
Query!
State/province [83]
0
0
Ota-ku
Query!
Country [84]
0
0
Japan
Query!
State/province [84]
0
0
Sapporo-shi
Query!
Country [85]
0
0
Japan
Query!
State/province [85]
0
0
Tokyo
Query!
Country [86]
0
0
Japan
Query!
State/province [86]
0
0
Toshima
Query!
Country [87]
0
0
Japan
Query!
State/province [87]
0
0
Yoshida-gun
Query!
Country [88]
0
0
Korea, Republic of
Query!
State/province [88]
0
0
Gyeonggi-do
Query!
Country [89]
0
0
Korea, Republic of
Query!
State/province [89]
0
0
Seoul
Query!
Country [90]
0
0
Korea, Republic of
Query!
State/province [90]
0
0
Wonju
Query!
Country [91]
0
0
Mexico
Query!
State/province [91]
0
0
Guadalajara
Query!
Country [92]
0
0
Mexico
Query!
State/province [92]
0
0
Zapopan
Query!
Country [93]
0
0
New Zealand
Query!
State/province [93]
0
0
Auckland
Query!
Country [94]
0
0
New Zealand
Query!
State/province [94]
0
0
Dunedin
Query!
Country [95]
0
0
New Zealand
Query!
State/province [95]
0
0
Tauranga
Query!
Country [96]
0
0
Poland
Query!
State/province [96]
0
0
Bialystok
Query!
Country [97]
0
0
Poland
Query!
State/province [97]
0
0
Krakow
Query!
Country [98]
0
0
Poland
Query!
State/province [98]
0
0
Kraków
Query!
Country [99]
0
0
Poland
Query!
State/province [99]
0
0
Lódz
Query!
Country [100]
0
0
Poland
Query!
State/province [100]
0
0
Poznan
Query!
Country [101]
0
0
Poland
Query!
State/province [101]
0
0
Proszowice
Query!
Country [102]
0
0
Poland
Query!
State/province [102]
0
0
Skarzysko-Kamienna
Query!
Country [103]
0
0
Poland
Query!
State/province [103]
0
0
Warszawa
Query!
Country [104]
0
0
Poland
Query!
State/province [104]
0
0
Wroclaw
Query!
Country [105]
0
0
Romania
Query!
State/province [105]
0
0
Bucharest
Query!
Country [106]
0
0
Romania
Query!
State/province [106]
0
0
Cluj-Napoca
Query!
Country [107]
0
0
Romania
Query!
State/province [107]
0
0
Craiova
Query!
Country [108]
0
0
Romania
Query!
State/province [108]
0
0
Timisoara
Query!
Country [109]
0
0
Russian Federation
Query!
State/province [109]
0
0
Kemerovo
Query!
Country [110]
0
0
Russian Federation
Query!
State/province [110]
0
0
Moscow
Query!
Country [111]
0
0
Russian Federation
Query!
State/province [111]
0
0
Novosibirsk
Query!
Country [112]
0
0
Russian Federation
Query!
State/province [112]
0
0
Ryazan
Query!
Country [113]
0
0
Russian Federation
Query!
State/province [113]
0
0
Saint Petersburg
Query!
Country [114]
0
0
Russian Federation
Query!
State/province [114]
0
0
Saint-Petersburg
Query!
Country [115]
0
0
Russian Federation
Query!
State/province [115]
0
0
Smolensk
Query!
Country [116]
0
0
Russian Federation
Query!
State/province [116]
0
0
St Petersburg
Query!
Country [117]
0
0
Russian Federation
Query!
State/province [117]
0
0
St. Petersburg
Query!
Country [118]
0
0
Russian Federation
Query!
State/province [118]
0
0
Tomsk
Query!
Country [119]
0
0
Serbia
Query!
State/province [119]
0
0
Belgrade
Query!
Country [120]
0
0
Slovakia
Query!
State/province [120]
0
0
Bardejov
Query!
Country [121]
0
0
Slovakia
Query!
State/province [121]
0
0
Bratislava
Query!
Country [122]
0
0
Slovakia
Query!
State/province [122]
0
0
Spisska Nova Ves
Query!
Country [123]
0
0
South Africa
Query!
State/province [123]
0
0
Cape Town
Query!
Country [124]
0
0
South Africa
Query!
State/province [124]
0
0
Durban
Query!
Country [125]
0
0
South Africa
Query!
State/province [125]
0
0
Gatesville
Query!
Country [126]
0
0
South Africa
Query!
State/province [126]
0
0
Johannesburg
Query!
Country [127]
0
0
South Africa
Query!
State/province [127]
0
0
Pretoria
Query!
Country [128]
0
0
Spain
Query!
State/province [128]
0
0
Alava
Query!
Country [129]
0
0
Spain
Query!
State/province [129]
0
0
Barcelona
Query!
Country [130]
0
0
Spain
Query!
State/province [130]
0
0
Madrid
Query!
Country [131]
0
0
Spain
Query!
State/province [131]
0
0
Sevilla
Query!
Country [132]
0
0
Spain
Query!
State/province [132]
0
0
Valencia
Query!
Country [133]
0
0
Turkey
Query!
State/province [133]
0
0
Ankara
Query!
Country [134]
0
0
Turkey
Query!
State/province [134]
0
0
Bursa
Query!
Country [135]
0
0
Turkey
Query!
State/province [135]
0
0
Canakkale
Query!
Country [136]
0
0
Turkey
Query!
State/province [136]
0
0
Izmir
Query!
Country [137]
0
0
Turkey
Query!
State/province [137]
0
0
Kirikkale
Query!
Country [138]
0
0
Turkey
Query!
State/province [138]
0
0
Mersin
Query!
Country [139]
0
0
Ukraine
Query!
State/province [139]
0
0
Dnepropetrovsk
Query!
Country [140]
0
0
Ukraine
Query!
State/province [140]
0
0
Donetsk
Query!
Country [141]
0
0
Ukraine
Query!
State/province [141]
0
0
Ivano-Frankivsk
Query!
Country [142]
0
0
Ukraine
Query!
State/province [142]
0
0
Kharkiv
Query!
Country [143]
0
0
Ukraine
Query!
State/province [143]
0
0
Kyiv
Query!
Country [144]
0
0
Ukraine
Query!
State/province [144]
0
0
Lviv
Query!
Country [145]
0
0
Ukraine
Query!
State/province [145]
0
0
Vinnytsya
Query!
Country [146]
0
0
Ukraine
Query!
State/province [146]
0
0
Yevpatoriya
Query!
Country [147]
0
0
Ukraine
Query!
State/province [147]
0
0
Zaporizhzhia
Query!
Country [148]
0
0
United Kingdom
Query!
State/province [148]
0
0
Chertsey
Query!
Country [149]
0
0
United Kingdom
Query!
State/province [149]
0
0
Cottingham
Query!
Country [150]
0
0
United Kingdom
Query!
State/province [150]
0
0
Dundee
Query!
Country [151]
0
0
United Kingdom
Query!
State/province [151]
0
0
Leeds
Query!
Country [152]
0
0
United Kingdom
Query!
State/province [152]
0
0
Teesside
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of lebrikizumab in participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroid (ICS) therapy and at least one second controller medication. Participants will be randomized in 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ("high" or "low") or placebo, administered subcutaneously (SC) every 4 weeks for 52 weeks, in addition to their standard-of-care therapy. This will be followed by a 52-week double-blind active treatment extension. During double-blind active treatment extension period, all participants will receive SC injection of lebrikizumab from Week 53 to Week 104. The anticipated time on study treatment is 104 weeks. After study treatment, all participants will complete a 20-week safety follow-up.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01867125
Query!
Trial related presentations / publications
Chen M, Shepard K 2nd, Yang M, Raut P, Pazwash H, Holweg CTJ, Choo E. Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma. Clin Exp Allergy. 2021 Apr;51(4):546-555. doi: 10.1111/cea.13790. Epub 2021 Jan 7. N Bauer R, Yang X, L Staton T, Olsson J, Holweg CTJ, R Arron J, Matthews JG, Choy DF. Seasonal variability of lung function and Asthma Quality of Life Questionnaire Scores in adults with uncontrolled asthma. BMJ Open Respir Res. 2019 Nov 11;6(1):e000406. doi: 10.1136/bmjresp-2019-000406. eCollection 2019. Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, Yokoyama A, Olsson J, Gray S, Holweg CT, Eisner M, Asare C, Fischer SK, Peng K, Putnam WS, Matthews JG. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med. 2016 Oct;4(10):781-796. doi: 10.1016/S2213-2600(16)30265-X. Epub 2016 Sep 5.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT01867125
Download to PDF